Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
Russell William Jenkins, Amir Reza Aref, Patrick Hall Lizotte et al. · Cancer Discovery · 2017
Abstract Ex vivo systems that incorporate features of the tumor microenvironment and model the dynamic response to immune checkpoint blockade (ICB) may facilitate efforts in precision immuno-oncology and the development of effective combination therapies. Here, we demonstrate the ability to interrogate ex vivo response to ICB using murine- and patient-derived organotypic tumor spheroids (MDOTS/PDOTS). MDOTS/PDOTS isolated from mouse and human tumors retain autologous lymphoid and myeloid cell populations and respond to ICB in short-term three-dimensional microfluidic culture. Response and resistance to ICB was recapitulated using MDOTS derived from established immunocompetent mouse tumor models. MDOTS profiling demonstrated that TBK1/IKKϵ inhibition enhanced response to PD-1 blockade, which effectively predicted tumor response in vivo. Systematic profiling of secreted cytokines in PDOTS captured key features associated with response and resistance to PD-1 blockade. Thus, MDOTS/PDOTS profiling represents a novel platform to evaluate ICB using established murine models as well as clinically relevant patient specimens. Significance: Resistance to PD-1 blockade remains a challenge for many patients, and biomarkers to guide treatment are lacking. Here, we demonstrate feasibility of ex vivo profiling of PD-1 blockade to interrogate the tumor immune microenvironment, develop therapeutic combinations, and facilitate precision immuno-oncology efforts. Cancer Discov; 8(2); 196–215. ©2017 AACR. See related commentary by Balko and Sosman, p. 143. See related article by Deng et al., p. 216. This article is highlighted in the In This Issue feature, p. 127
Cited by 587 works. doi:10.1158/2159-8290.cd-17-0833
Authors
- Russell William Jenkins
- Amir Reza Aref
- Patrick Hall Lizotte
- Elena V. Ivanova
- Susanna Stinson
- Chensheng Willa Zhou
- Michaela Bowden
- Jiehui Deng
- Hongye Liu
- Diana Miao
- Meng Xiao He
- Gao Zhang
- Tian Tian
- Chaoran Cheng
- Zhi Wei
- Sangeetha S. Palakurthi
- Mark A. Bittinger
- Hans Vitzthum
- Jong Wook Kim
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- edgeR : a Bioconductor package for differential expression analysis of digital gene expression data
- The blockade of immune checkpoints in cancer immunotherapy
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy